| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
|
N Engl J Med
|
2015
|
4.26
|
|
2
|
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
|
N Engl J Med
|
2008
|
3.71
|
|
3
|
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.
|
Clin Infect Dis
|
2003
|
2.54
|
|
4
|
Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.
|
Soc Sci Med
|
2002
|
2.33
|
|
5
|
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.
|
AIDS
|
2002
|
2.21
|
|
6
|
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.
|
Am J Respir Crit Care Med
|
2007
|
2.03
|
|
7
|
Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.
|
J Infect Dis
|
2002
|
1.90
|
|
8
|
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
|
PLoS Med
|
2004
|
1.89
|
|
9
|
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.
|
Clin Infect Dis
|
2002
|
1.57
|
|
10
|
Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study.
|
Antivir Ther
|
2003
|
1.55
|
|
11
|
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults.
|
AIDS
|
2009
|
1.46
|
|
12
|
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
|
AIDS
|
2008
|
1.42
|
|
13
|
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.
|
JAMA
|
2004
|
1.42
|
|
14
|
Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.
|
J Antimicrob Chemother
|
2009
|
1.39
|
|
15
|
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
|
J Acquir Immune Defic Syndr
|
2005
|
1.29
|
|
16
|
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.
|
AIDS
|
2004
|
1.28
|
|
17
|
Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.
|
J Acquir Immune Defic Syndr
|
2009
|
1.25
|
|
18
|
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
|
Clin Infect Dis
|
2009
|
1.23
|
|
19
|
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
|
Antimicrob Agents Chemother
|
2009
|
1.17
|
|
20
|
European bat Lyssavirus transmission among cats, Europe.
|
Emerg Infect Dis
|
2009
|
1.15
|
|
21
|
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
|
Antimicrob Agents Chemother
|
2004
|
1.05
|
|
22
|
Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
|
PLoS One
|
2011
|
1.05
|
|
23
|
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
|
Eur J Clin Pharmacol
|
2006
|
1.04
|
|
24
|
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
|
J Infect Dis
|
2011
|
1.04
|
|
25
|
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.
|
Clin Infect Dis
|
2004
|
1.03
|
|
26
|
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
|
J Clin Virol
|
2005
|
1.03
|
|
27
|
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
|
Clin Infect Dis
|
2012
|
1.02
|
|
28
|
Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients.
|
Eur J Hum Genet
|
2005
|
1.00
|
|
29
|
Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study.
|
J Acquir Immune Defic Syndr
|
2009
|
1.00
|
|
30
|
Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).
|
Int J Drug Policy
|
2007
|
0.98
|
|
31
|
Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.
|
Clin Infect Dis
|
2002
|
0.97
|
|
32
|
Legionella pneumophila Arthritis: use of medium specific for Mycobacteria for isolation of L. pneumophila in culture of articular fluid specimens.
|
Clin Infect Dis
|
2002
|
0.96
|
|
33
|
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
|
J Med Virol
|
2005
|
0.96
|
|
34
|
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
|
Eur J Clin Pharmacol
|
2004
|
0.95
|
|
35
|
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
|
J Antimicrob Chemother
|
2008
|
0.95
|
|
36
|
Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.
|
Br J Clin Pharmacol
|
2005
|
0.94
|
|
37
|
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study.
|
J Infect Dis
|
2002
|
0.94
|
|
38
|
Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
|
Antivir Ther
|
2002
|
0.92
|
|
39
|
Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial.
|
J Acquir Immune Defic Syndr
|
2005
|
0.92
|
|
40
|
Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8).
|
Qual Life Res
|
2007
|
0.91
|
|
41
|
Prolonged hepatitis A infection in an HIV-1 seropositive patient.
|
J Med Virol
|
2002
|
0.88
|
|
42
|
[Mortality rate of HIV-infected adults compared with the general population: long-term and CD4-lymphocyte-dependent results].
|
Med Sci (Paris)
|
2008
|
0.88
|
|
43
|
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
|
J Antimicrob Chemother
|
2012
|
0.87
|
|
44
|
Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.
|
J Infect Dis
|
2002
|
0.87
|
|
45
|
The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination.
|
AIDS
|
2003
|
0.87
|
|
46
|
Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy.
|
AIDS Res Hum Retroviruses
|
2012
|
0.86
|
|
47
|
Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
|
Ther Drug Monit
|
2007
|
0.83
|
|
48
|
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).
|
Antivir Ther
|
2007
|
0.83
|
|
49
|
How do HIV-infected smokers react to cigarette price increases? Evidence from the APROCO-COPILOTE-ANRS CO8 Cohort.
|
Curr HIV Res
|
2009
|
0.83
|
|
50
|
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.
|
Clin Infect Dis
|
2001
|
0.83
|
|
51
|
Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers.
|
AIDS
|
2016
|
0.83
|
|
52
|
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
|
Antimicrob Agents Chemother
|
2011
|
0.82
|
|
53
|
A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.
|
Eur J Clin Pharmacol
|
2005
|
0.81
|
|
54
|
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
|
Ther Drug Monit
|
2005
|
0.81
|
|
55
|
Incidence, medical and socio-behavioural predictors of psychiatric events in an 11-year follow-up of HIV-infected patients on antiretroviral therapy.
|
Antivir Ther
|
2012
|
0.81
|
|
56
|
Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.
|
HIV Clin Trials
|
2005
|
0.81
|
|
57
|
Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials.
|
HIV Clin Trials
|
2006
|
0.81
|
|
58
|
Low alcohol consumption as a predictor of higher CD4+ cell count in HIV-treated patients: a french paradox or a proxy of healthy behaviors? The ANRS APROCO-COPILOTE CO-08 cohort.
|
J Acquir Immune Defic Syndr
|
2014
|
0.81
|
|
59
|
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection.
|
AIDS Rev
|
2010
|
0.80
|
|
60
|
Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE.
|
Clin Infect Dis
|
2009
|
0.80
|
|
61
|
Adherence to and effectiveness of highly active antiretroviral treatment for HIV infection: assessing the bidirectional relationship.
|
Med Care
|
2012
|
0.80
|
|
62
|
Prevalence and predictors of deterioration of a trustful patient-provider relationship among HIV-infected persons treated with antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2008
|
0.80
|
|
63
|
Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
|
Antivir Ther
|
2006
|
0.79
|
|
64
|
Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy.
|
BMJ Open
|
2012
|
0.79
|
|
65
|
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.
|
J Antimicrob Chemother
|
2010
|
0.79
|
|
66
|
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
|
J Acquir Immune Defic Syndr
|
2003
|
0.78
|
|
67
|
Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
|
J Antimicrob Chemother
|
2011
|
0.78
|
|
68
|
R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.
|
Antimicrob Agents Chemother
|
2003
|
0.78
|
|
69
|
Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.
|
J Acquir Immune Defic Syndr
|
2015
|
0.78
|
|
70
|
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
|
Antimicrob Agents Chemother
|
2012
|
0.78
|
|
71
|
Thrombocytopenia during primary HIV-1 infection predicts the risk of recurrence during chronic infection.
|
J Acquir Immune Defic Syndr
|
2012
|
0.78
|
|
72
|
Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).
|
J Int Assoc Physicians AIDS Care (Chic)
|
2008
|
0.78
|
|
73
|
Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
|
Antivir Ther
|
2013
|
0.77
|
|
74
|
Short communication: Paraoxonase 1 (PON1) in French HIV-infected patients under antiretroviral therapy: relationship with the metabolic syndrome and inflammation.
|
AIDS Res Hum Retroviruses
|
2013
|
0.77
|
|
75
|
Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort.
|
Antivir Ther
|
2015
|
0.77
|
|
76
|
Final analysis of the Trilège induction-maintenance trial: results at 18 months.
|
AIDS
|
2002
|
0.77
|
|
77
|
No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach.
|
Ther Drug Monit
|
2005
|
0.77
|
|
78
|
Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
|
Antivir Ther
|
2008
|
0.77
|
|
79
|
Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE study.
|
AIDS Res Hum Retroviruses
|
2011
|
0.77
|
|
80
|
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
|
AIDS
|
2015
|
0.76
|
|
81
|
Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
|
J Med Virol
|
2013
|
0.76
|
|
82
|
The immune response to the RT181-189 epitope in HIV-1-infected patients is associated with viral sequence polymorphism flanking the epitope.
|
J Clin Immunol
|
2011
|
0.76
|
|
83
|
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
|
Fundam Clin Pharmacol
|
2008
|
0.76
|
|
84
|
Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
|
Antivir Ther
|
2006
|
0.76
|
|
85
|
Improving diagnostic criteria for Propionibacterium acnes osteomyelitis: a retrospective analysis.
|
Scand J Infect Dis
|
2010
|
0.76
|
|
86
|
Despite an impaired response to IL-7, CD4+EM T cells from HIV-positive patients proliferate normally in response to IL-15 and its superagonist, RLI.
|
AIDS
|
2011
|
0.76
|
|
87
|
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
88
|
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
89
|
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
|
PLoS One
|
2016
|
0.75
|
|
90
|
Prolonged viral suppression over a 12-year follow-up of HIV-infected patients: the persistent impact of adherence at 4 months after initiation of combined antiretroviral therapy in the ANRS CO8 APROCO-COPILOTE cohort.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
91
|
[Meningitis with direct negative bacteriological examination. Prospective assessment of a decision making tree].
|
Presse Med
|
2004
|
0.75
|
|
92
|
Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART.
|
AIDS
|
2006
|
0.75
|
|
93
|
Incidence and risk factors for recurrent sexually transmitted infections among men who have sex with men on HIV pre-exposure prophylaxis.
|
AIDS
|
2022
|
0.75
|
|
94
|
Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.
|
J Med Virol
|
2013
|
0.75
|
|
95
|
Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study.
|
J Med Virol
|
2012
|
0.75
|
|
96
|
Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives.
|
AIDS
|
2017
|
0.75
|
|
97
|
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
|
AIDS Res Hum Retroviruses
|
2012
|
0.75
|
|
98
|
Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort.
|
J Acquir Immune Defic Syndr
|
2008
|
0.75
|
|
99
|
Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.
|
Fundam Clin Pharmacol
|
2011
|
0.75
|
|
100
|
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.
|
J Antimicrob Chemother
|
2017
|
0.75
|
|
101
|
Information that should be given to HIV cohort participants during ongoing research: the viewpoints of patient representatives and research professionals.
|
J Empir Res Hum Res Ethics
|
2011
|
0.75
|
|
102
|
Sub-Saharan Africa migrants have slower initial CD4 cell recovery after cART initiation than French natives, regardless of living conditions.
|
AIDS
|
2017
|
0.75
|
|
103
|
Changes in Cognitive Function Over 96 weeks in Naïve Patients Randomised to Darunavir-ritonavir plus either Raltegravir or Tenofovir-Emtricitabine: a substudy of the NEAT001/ANRS143 trial.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
104
|
Disturbance of apolipoprotein B100 containing lipoprotein metabolism in severe hyperlipidemic and lipodystrophic HIV patients on combined antiretroviral therapy: evidences of insulin resistance effect.
|
Med Chem
|
2008
|
0.75
|
|
105
|
Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines.
|
J Acquir Immune Defic Syndr
|
2010
|
0.75
|
|
106
|
Prevalence of Mycoplasma genitalium Infection and Relationship with Symptoms Among Adults Attending a Sexual Health Centre.
|
Acta Derm Venereol
|
2016
|
0.75
|
|
107
|
Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
|
Scand J Infect Dis
|
2011
|
0.75
|
|
108
|
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
|
AIDS
|
2017
|
0.75
|